Search companies

Live

Tuesday, 17 November 2026 · 564 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

PYC Therapeutics Meets Kidney Disease Trial Enrolment Target

PYC: $1.84 -4.18% · MC: $1.9B

PYC Therapeutics has met its interim enrolment target of 24 patients in the Phase 1b repeat-dose study of PYC-003 for polycystic kidney disease and will continue recruiting. The company aims to report kidney volume data for at least 24 patients in calendar 2027 and progress to a potentially registrational Phase 2/3 trial in 2028, subject to regulatory alignment and patient dropout assumptions. It also expects to present data from the ongoing study and its open-label extension in 2027.

Source announcements: 2026-11-13 08:48 to 2026-11-13 08:48 Sydney time
Story updated 2026-11-13 11:01 Sydney time
SourcesPKD Program - Enrolment Target Met
Comments